Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T21:38:46.574Z.
Calculation as of: 2026-10-06T21:38:46.574Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f531a2535853470732a06f34d6c515690d92043f5f74c4447600e4211480c4c2
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Tonix Pharmaceuticals Holding Corp.
Market Cap
$122.66M
Price/FCF Ratio
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO |
|---|---|---|
| Tonix Pharmaceuticals Holding Corp. (TNXP) | $122.66M | N/A |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | N/A |
| Entera Bio Ltd. (ENTX)vs › | $124.70M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.58M | N/A |
| Seer, Inc. (SEER)vs › | $120.41M | N/A |
| Cibus, Inc. (CBUS)vs › | $119.84M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.83M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $118.59M | N/A |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
